The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2021 | Early allogeneic transplantation for myelofibrosis patients responding to ruxolitinib
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, discusses the role of early allogeneic transplantation for patients with primary myelofibrosis who respond to JAK2 inhibition. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
Disclosures
Juan Carlos Hernández-Boluda, MD, PhD, has received advisory honoraria from BMS and AOP Pharma; travel support from Incyte and Pfizer; and speaker fees from Pfizer, Novartis and Incyte.
